[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-366945-105":59,"doc-detail-366945-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","cancer-associated-fibroblasts-as-a-potential-therapeutic-target-for-thyroid-cancers","Cancer-associated fibroblasts as a potential therapeutic target for thyroid cancers","","Thyroid cancer is an endocrine malignancy shaped by the tumor microenvironment, where cancer-associated fibroblasts (CAFs) drive disease progression. CAFs promote a pro-tumorigenic niche through cytokine secretion and extracellular matrix (ECM) stiffening, supporting targeting strategies. CAF-mediated ECM remodeling, angiogenesis, and epithelial–mesenchymal transition (EMT) also enhance invasion, metastasis, and immune evasion, contributing to therapy resistance. Preclinical models and emerging clinical trials suggest that CAF inhibition can reduce tumor burden and improve drug sensitivity, while key challenges remain.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cancer-associated-fibroblasts-as-a-potential-therapeutic-target-for-thyroid-cancers/366945/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cancer-associated-fibroblasts-as-a-potential-therapeutic-target-for-thyroid-cancers/366945.png","ImageObject",300,407,{"name":92,"@type":93},"CatatanPagi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"How do cancer-associated fibroblasts (CAFs) contribute to thyroid cancer progression?","Question",{"text":113,"@type":114},"CAFs support a pro-tumorigenic niche by secreting cytokines and stiffening the extracellular matrix. They also drive ECM remodeling, angiogenesis, and epithelial–mesenchymal transition (EMT), which together promote invasion, metastasis, and immune evasion.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What therapeutic approaches have been evaluated to disrupt CAF function in thyroid cancers?",{"text":118,"@type":114},"Strategies discussed include small molecule inhibitor-based therapies, immune-based therapies, nanoparticle-based approaches, and combination regimens. These aim to impair CAF functionality and counter tumor growth and treatment resistance.",{"name":120,"@type":111,"acceptedAnswer":121},"What evidence supports CAF inhibition in thyroid cancer models and trials?",{"text":122,"@type":114},"Preclinical studies using thyroid cancer models show reduced tumor burden and improved drug sensitivity after CAF inhibition. Emerging clinical trials have also tested CAF-directed agents in patient cohorts and reported supportive findings.",{"name":124,"@type":111,"acceptedAnswer":125},"What major challenges must be addressed for CAF-targeted therapy to advance?",{"text":126,"@type":114},"Key challenges include identifying reliable CAF-specific biomarkers, optimizing treatment timing, and integrating biomarkers into personalized medicine frameworks to maximize clinical benefit.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},366945,1790198427,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":144,"language":145,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":67,"update_tm":149,"read_time":150,"preview_page_count":19,"preview_urls":151},962090894170,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Cancer-associated fibroblasts as a potential therapeutic target for thyroid cancers  \nKashmira Chakraborty, MTecha , Ramya Lakshmi Rajendran, PhDb,c,d , Shristy Kothiwal, MSce ,  \nSourav Majhi, MTechf , Anuvab Dey, MTechf, Subhrojyoti Ghosh, MTechg , Ankita Chowdhury, MTechh , Chandrajeet Dhara, MTechi , Rijula Batabyal, BTechj , Sreyee Biswas, MTechj , Chae Moon Hong, MD, PhDc,d, k , Prakash Gangadaran, PhDc,d ,*, Byeong-Cheol Ahn, MD, PhDb,c,d, k ,*  \nAbstract  \nThyroid cancer, a prevalent endocrine malignancy, is influenced by its tumor microenvironment (TME), with cancer-associated fibroblasts (CAFs) playing a pivotal role in disease progression. Molecularly, CAFs orchestrate a pro-tumorigenic niche via cytokine secretion and extracellular matrix (ECM) stiffening, underscoring their targetability. Therapeutic strategies, including small molecule inhibitor-based therapies, immune-based therapies, nanoparticle-based approaches, and combination regimens, have been evaluated for their efficacy in disrupting CAF functionality. CAFs from resident fibroblasts or recruited precursors can promote the progression of thyroid cancer through ECM remodeling, angiogenesis, and epithelial–mesenchymal transition (EMT) induction while facilitating immune evasion. These processes can enhance tumor invasiveness, metastasis, and resistance to conventional therapies. Preclinical studies using thyroid cancer models have demonstrated promising outcomes, such as reduced tumor burden and enhanced drug sensitivity upon CAF inhibition. Emerging clinical trials have tested CAF-directed agents in patient cohorts and validated these findings. However, many challenges persist, including the identification of reliable CAF-specific biomarkers, optimization of treatment timing, and integration of the biomarkers into personalized medicine frameworks. This review explores the therapeutic potential of CAFs for thyroid cancers, emphasizing their origin, activation, and multifaceted contributions to tumor growth. This review synthesizes current evidence, highlighting CAFs as a novel therapeutic frontier for thyroid cancers. Future research should focus on refined biomarker discovery and strategic therapeutic sequencing to maximize clinical benefits, providing a roadmap for translating CAF-targeted approaches into effective treatments for thyroid cancers.  \nKeywords: cancer-associated fibroblast, epithelial–mesenchymal transition, extracellular matrix, inhibitor, thyroid cancer  \naDepartment of Chemistry and Chemical Biology, Indian Institute of Technology (Indian School of Mines), Dhanbad, Jharkhand, India, bBK21 FOUR KNU Convergence Educational Program of Biomedical Sciences for Creative Future Talents, Department of Biomedical Sciences, School of Medicine, Kyungpook National University, Daegu, Republic of Korea, cDepartment of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea, dCardiovascular Research Institute, Kyungpook National University, Daegu, Republic of Korea, eInfection Biology Group, CSIR-Centre for Cellular and Molecular Biology, Hyderabad, Telangana, India, fDepartment of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, North Guwahati, Assam, India, gDepartment of Biotechnology, Indian Institute of Technology Madras, Chennai, India, hDepartment ofBiochemical Engineering and Biotechnology, Indian Institute of Technology Delhi, New Delhi, India, iDepartment of Biotechnology, Jaypee Institute of Information Technology Noida, Uttar Pradesh, India, jDepartment of Biotechnology and Medical engineering , National Institute of Technology , Rourkela, India and kDepartment of Nuclear Medicine, Kyungpook National University Hospital, Daegu, Republic of Korea  \nK.C., R.L.R., S.K., S.M., A.D., and S.G. equally contributed to this work. Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.  \n*Corresponding author. Address: Department of Nuc","cbCaiqW041eBTMMN","https://ap.wps.com/l/cbCaiqW041eBTMMN","pdf",2120918,17,"English","# Introduction\n## Thyroid cancer overview\n## Tumor microenvironment and CAFs\n## CAF therapeutic targeting strategies\n## Challenges and future directions","[{\"question\":\"How do cancer-associated fibroblasts (CAFs) contribute to thyroid cancer progression?\",\"answer\":\"CAFs support a pro-tumorigenic niche by secreting cytokines and stiffening the extracellular matrix. They also drive ECM remodeling, angiogenesis, and epithelial–mesenchymal transition (EMT), which together promote invasion, metastasis, and immune evasion.\"},{\"question\":\"What therapeutic approaches have been evaluated to disrupt CAF function in thyroid cancers?\",\"answer\":\"Strategies discussed include small molecule inhibitor-based therapies, immune-based therapies, nanoparticle-based approaches, and combination regimens. These aim to impair CAF functionality and counter tumor growth and treatment resistance.\"},{\"question\":\"What evidence supports CAF inhibition in thyroid cancer models and trials?\",\"answer\":\"Preclinical studies using thyroid cancer models show reduced tumor burden and improved drug sensitivity after CAF inhibition. Emerging clinical trials have also tested CAF-directed agents in patient cohorts and reported supportive findings.\"},{\"question\":\"What major challenges must be addressed for CAF-targeted therapy to advance?\",\"answer\":\"Key challenges include identifying reliable CAF-specific biomarkers, optimizing treatment timing, and integrating biomarkers into personalized medicine frameworks to maximize clinical benefit.\"}]","Cancer-associated fibroblasts as a potential therapeutic target for thyroid cancers | PDF",1790168314,43,[152,156,160,164],{"page_no":8,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d35eb600ad0b1937437b669e12f68135.webp",983,1310,{"page_no":14,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cd5ed503506186faeea341b9858e2638.webp",982,1309,{"page_no":81,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5641aaf7ff4bbd9910f5269e0583f83f.webp",981,1308,{"page_no":19,"url":165,"width":166,"height":167},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/894bb40d7cf353b5ed530fa83b5eef2c.webp",980,1306]